CTLA4 and cancer: Considering that ICB cancer immunotherapy works by inhibiting key immune checkpoints, we assessed certain representative molecules and discovered that PD-1, PD-L1, and CTLA4 were significantly more increasingly expressed in the high RiskScore group (Figure 12D).